

Provider Bulletin [Date]

Medical Policies and Clinical Utilization Management Guidelines update

Medical Policies update

On [November 21, 2018], the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Healthy Blue. These policies were developed or revised to support clinical coding edits. Several policies were revised to provide clarification only and are not included in the below listing.

The *Medical Policies* were made publicly available on the Healthy Blue provider website on the effective date listed below. Visit [https://provider.healthybluela.com/louisiana-provider/medical-policies-and-clinical-guidelines] to search for specific policies.

Please note:

- *CG-BEH-01 Screening and Assessment for Autism Spectrum Disorders and Rett Syndrome* was revised to add tests for metabolic markers in the blood, urine, tissue or other biologic materials (also known as metabolomics), including but not limited to amino acid dysregulation metabotype testing as not medically necessary.
- *CG-SURG-27 Sex Reassignment Surgery* the medical necessity statement was revised to add criteria requiring referral letters to mastectomy.
- AIM criteria updates include:
 - Musculoskeletal Interventional Pain Management*
 - o Advanced Imaging Imaging of the Chest

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

Please note: For markets with pharmacy services carved out, the applicable listings below would be informational only.

Publish date	Medical Policy number	Medical Policy title	New or revised
[12/12/2018	MED.00126	Fractional Exhaled Nitric Oxide and	New
		Exhaled Breath Condensate Measurements	
		for Respiratory Disorders	
11/15/2018	MED.00109	Corneal Collagen Cross-Linking	Revised
12/12/2018	TRANS.00024	Hematopoietic Stem Cell Transplantation	Revised
		for Select Leukemias and Myelodysplastic	
		Syndrome	
11/15/2018]	SURG.00120	Internal Rib Fixation Systems	Revised

Clinical Utilization Management (UM) Guidelines update

On [November 21, 2018], the MPTAC approved the following *Clinical UM Guidelines* applicable to Healthy Blue. These *Clinical UM Guidelines* were developed or revised to support clinical coding edits. Several guidelines were revised to provide clarification only and are not included in the following listing. This list represents the *Clinical UM Guidelines* adopted by the Medical Operations Committee for the Government Business Division on [January 3, 2019].

On [November 21, 2018], the *Clinical UM Guidelines* were made publicly available on the Healthy Blue *Medical Policies* and *Clinical UM Guidelines* subsidiary website. Visit [https://provider.healthybluela.com/louisiana-provider/medical-policies-and-clinical-guidelines] to search for specific guidelines.

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

Please note: For markets with pharmacy services carved out, the applicable listings below would be informational only.

Publish date	Clinical UM Guideline number	Clinical UM Guideline title	New or revised
[12/12/2018	CG-BEH-01*	Screening and Assessment for Autism Spectrum Disorders and Rett Syndrome	Revised
12/12/2018	CG-GENE-03	BRAF Mutation Analysis	Revised
12/12/2018	CG-LAB-14	Respiratory Viral Panel Testing in the Outpatient Setting	New
12/12/2018	CG-MED-78	Anesthesia Services for Interventional Pain Management Procedures	New
12/12/2018	CG-SURG-27*	Sex Reassignment Surgery	Revised
12/12/2018	CG-SURG-91	Minimally Invasive Ablative Procedures for Epilepsy	New
12/12/2018	CG-THER-RAD-03	Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy	Revised
1/3/2019	CG-MED-79	Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing Systems	New
1/3/2019]	CG-MED-80	Positron Emission Tomography (PET) and PET/CT Fusion	New